图书简介
About 7 million people worldwide are suffering from various inherited neuromuscular diseases. Gene therapy brings the hope of treating these diseases at their genetic roots. Muscle Gene Therapy is the only book dedicated to this topic. The first edition was published in 2010 when the field was just about to enter its prime time. The progress made since then has been unprecedented. The number of diseases that have been targeted by gene therapy has increased tremendously. The gene therapy toolbox is expanded greatly with many creative novel strategies (such as genome editing and therapy with disease-modifying genes). Most importantly, clinical benefits have begun to emerge in human patients. To reflect rapid advances in the field, we have compiled the second edition of Muscle Gene Therapy with contributions from experts that have conducted gene therapy studies either in animal models and/or in human patients. The new edition offers a much needed, up-to-date overview and perspective on the foundation and current status of neuromuscular disease gene therapy. It provides a framework to the development and regulatory approval of muscle gene therapy drugs in the upcoming years. This book is a must-have for anyone who is interested in neuromuscular disease gene therapy including those in the research arena (established investigators and trainees in the fields of clinical practice, veterinary medicine and basic biomedical sciences), funding and regulatory agencies, and patient community.
Part 1 Foundations for muscle gene therapy.-Chapter 1. An overview of muscle biology and physiology for muscle gene therapy.-Chapter 2. Molecular basis of muscle disease.-Chapter 3. Animal models for muscle disease and muscle gene therapy.-Chapter 4. Muscle stem cell biology and implication in gene therapy.-Chapter 5. Pluripotent stem cells for gene therapy of hereditary muscle disorders.-Chapter 6. MicroRNAs (miRs) in muscle gene therapy.-Chapter 7. Immune system regulation of muscle injury and disease.-Chapter 8. Design of muscle gene therapy expression cassette.-Chapter 9 Non-viral vector mediated muscle gene therapy.- Chapter 10. Viral vectors for muscle gene therapy.-Chapter 11. Development of next generation muscle gene therapy AAV vectors.-Chapter 12. Histological and biochemical evaluation of muscle gene therapy.-Chapter 13. Optical polarization tractography imaging of structural changes in the skeletal and cardiac muscles of the mdx4cv mice.-Chapter 14. Biomarkers for muscle disease gene therapy.-Chapter 15. Large-scale clinical manufacturing of AAV Vectors for systemic muscle gene therapy.-Chapter 16. Genome-editing for muscle gene therapy.-Part 2 Preclinical muscle gene therapy.-Chapter 17. Considerations on preclinical muscle gene therapy studies.-Chapter 18. Gene replacement therapy for Duchenne muscular dystrophy.- Chapter 19. Recent advances in AON-mediated exon-skipping therapy for Duchenne muscular dystrophy.-Chapter 20. AAV-mediated exon-skipping therapy for Duchenne muscular dystrophy.-Chapter 21. Alternate translational initiation of dystrophin: a novel therapeutic approach.-Chapter 22. Genome editing for Duchenne muscular dystrophy.-Chapter 23. Sarcolipin knockdown therapy for Duchenne muscular dystrophy.-Chapter 24. Gene therapy for central nervous system in Duchenne muscular dystrophy.-Chapter 25. Therapeutic approach for dysferlinopathy in animal models.-Chapter 26. Muscle cell membrane repair and therapeutic implications.-Chapter 27. Treatment of muscular dystrophy-dystroglycanopathy: unlocking the potential of genetic engineering.-Chapter 28. RNAi therapy for dominant muscular dystrophies and other myopathies.-Chapter 29. Gene therapy for facioscapulohumeral muscular dystrophy (FSHD).-Chapter 30. Gene therapy and gene editing for myotonic dystrophy.-Chapter 31. Gene therapy for oculopharyngeal muscular dystrophy.-Chapter 32. Gene therapy for X-linked myotubular myopathy.-Chapter 33. Pre-clinical gene therapy studies for metabolic myopathy.- Chapter 34 Elimination of mutant mitochondrial DNA in mitochondrial myopathies using gene editing enzymes.-Chapter 35. Gene therapy for Charcot-Marie-Tooth inherited neuropathy.- Chapter 36. Muscle - a potent target in vaccination.-Part 3 Clinical muscle gene therapy.- Chapter 37. Patient and family perspective on muscle gene therapy.-Chapter 38. Design of clinical trials for gene therapy in muscular dystrophy.-Chapter 39. Path to clinical trials: trial design, development of the clinical product and safety concerns in the implementation of clinical trials.-Chapter 40. Muscle MRI as an endpoint in clinical trials.-Chapter 41. Gene therapy clinical trials for Duchenne and limb girdle muscular dystrophies lessons learned.-Chapter 42. Duchenne muscular dystrophy exon-skipping trials.-Chapter 43. What we have learned from 10 years of DMD exon skipping trials.-Chapter 44. Clinical gene therapy trials for Pompe disease.- Chapter 45. Muscle-directed gene therapy for alpha-1 antitrypsin deficiency.
Trade Policy 买家须知
- 关于产品：
- ● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
- ● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
- ● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
关于退换货：- 由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
并请在工作日通过电话400-008-1110联系我们。
- 签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
- ● 缺页/错页/错印/脱线
关于发货时间：- 一般情况下：
- ●【现货】 下单后48小时内由北京（库房）发出快递。
- ●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
- ● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
- ● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
关于到货时间：- 由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间：- 010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
- 其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
关于快递：- ● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐
